HNC: Human Neural Circuits Electrophysiology During Cognition
NCT05962424
Recruiting
The purpose of this study is to understand how ketamine brings about dissociative symptoms.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/24/2024
Locations: Stanford University, Palo Alto, California
Conditions: Psychiatric Disorder
Register for Updates
Understanding Ketamine's Dissociative Effects (KD Study)
NCT04861051
Recruiting
The purpose of this study is to understand how ketamine brings about dissociative symptoms.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/24/2024
Locations: Stanford University School of Medicine, Palo Alto, California
Conditions: Epilepsy
Register for Updates
Brain Network Dynamics of Depression During Esketamine Treatment
NCT06012916
Completed
This is a monocentric, observational clinical trial investigating the effect of Esketamine on brain network activity and a belief updating task in people with depression. We investigate the immediate and the long-term effect (approx. 8 weeks) of Esketamine on EEG signals, pupillometry and belief updating and the relation of those effects on depressive symptomatology.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
09/13/2024
Locations: Carolina Center for Neurostimulation, Chapel Hill, North Carolina
Conditions: Depressive Disorder, Major
Register for Updates
Oral Ketamine for Treatment of Vaso-Occlusive Pain
NCT05378555
Recruiting
The purpose of this study is to learn more about the feasibility of oral ketamine for the treatment of painful sickle-cell crises in children and adolescents as a supplement to intravenous (IV) opioids. There is a need for improved non-opioid analgesia for patients experiencing sickle-cell crises in the hospital and prehospital setting, as children and adolescents with sickle cell disease who experience sickle-cell crises often have severe pain that is not well controlled by high dose opioids, l... Read More
Gender:
ALL
Ages:
Between 12 years and 24 years
Trial Updated:
08/30/2024
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Vaso-occlusive Crisis
Register for Updates
KET-RO Plus RO DBT for Treatment Resistant Depression
NCT06138691
Active Not Recruiting
This pilot study will assess the safety and feasibility of intravenous (IV) ketamine combined with RO DBT in young adults with Treatment-Resistant Depression (TRD). In addition, this study will develop and utilize innovative methodological approaches to demonstrate the feasibility of precision medicine with this type of therapy.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/29/2024
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Treatment Resistant Depression
Register for Updates
Comparative Effectiveness of ECT vs. KETAMINE Over the Lifespan
NCT06034821
Enrolling By Invitation
This study is a randomized open-label single-blind non-inferiority comparative effectiveness study of ECT vs. KET for the treatment of Acute Suicidal Depression (ASD).
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
08/26/2024
Locations: University of Arizona, Tucson, Arizona +10 locations
Conditions: Acute Suicidal Depression (ASD)
Register for Updates
Ketamine in Severe Traumatic Brain Injury
NCT06062628
Recruiting
Traumatic brain injury (TBI) accounts for approximately 2.5 million visits to emergency departments in the United States each year. After decades of research, management strategies for severe TBI (sTBI) patients are still evolving. Optimizing intracranial pressure (ICP) and cerebral perfusion pressure (CPP) are paramount in the management of these patients and placement of these monitors is the current standard-of-care. However, monitoring brain oxygenation (PbtO2) with invasive intraparenchymal... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/26/2024
Locations: Parkland Memorial Hospital, Dallas, Texas
Conditions: Traumatic Brain Injury, Traumatic Encephalopathy
Register for Updates
Imaging SV2A in Mood Disorders
NCT02734602
Recruiting
This study is designed to examine SV2A density in MDD and PTSD as a correlate of synaptic density, and to determine whether ketamine administration will reverse the synaptic loss in vivo in human subjects. To our knowledge, this is the first human study to examine SV2A in vivo in MDD and PTSD and to use the first known drug (ketamine) that rapidly reverses synaptic loss to determine whether ketamine administration could restore some of the structural changes associated with depression and PTSD.... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
08/08/2024
Locations: PET Center, New Haven, Connecticut
Conditions: Major Depressive Disorder, Post-Traumatic Stress Disorder
Register for Updates
EEG Characteristics in ECT
NCT04022226
Completed
The investigators will be examining slow-wave characteristics in depressed patients receiving electroconvulsive therapy (ECT) using direct current electroencephalogram (dcEEG) by anesthesia induction agent.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/05/2024
Locations: University of New Mexico Mental Health Center, Albuquerque, New Mexico
Conditions: Electroconvulsive Therapy, Direct Current Electroencephalogram, Ketamine, Spreadind Depression
Register for Updates
Ketamine for the Treatment of Opioid Use Disorder and Depression
NCT04177706
Completed
The purpose of the study is to examine whether an investigational medication called ketamine is able to improve treatment outcomes for concurrent opioid addiction and depression when used in conjunction with buprenorphine treatment. Study medications will be delivered twice per week for four weeks. If you are eligible and you decide to enroll in the study, your participation will last approximately 8 weeks, or 2 months.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/31/2024
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Depression, Opioid-use Disorder, Opioid Abuse
Register for Updates
Ketamine + Mindfulness for Depression
NCT05168735
Completed
In this project, the investigators will administer a single infusion of IV ketamine to depressed patients and randomize the patients to receive either a) usual/typical infusion conditions or b) mindfulness training and exercises in conjunction with the infusion. Investigators will test whether the conjunction of ketamine + mindfulness enhances the reductions in depression following a single ketamine infusion.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/30/2024
Locations: Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania
Conditions: Depression, Unipolar
Register for Updates
Repeated Neurocognitive Measurements in Depressed Patients
NCT04916548
Completed
In this project, we will A) track the functioning of a collection of potential neurobiological targets for depression over time, B) examine how fluctuations in the functioning of those targets relates to real-world functioning, and C) in a subset of the sample, determine how the functioning in those targets is altered by a single dose of ketamine.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
07/30/2024
Locations: Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania
Conditions: Depression, Unipolar
Register for Updates